Collaborations, New Studies, and New Drug Applications - Research Report on Amgen, Gilead, Abbott, Biogen Idec, and UnitedHealth

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, September 16, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Amgen, Inc. (NASDAQ: AMGN), Gilead Sciences, Inc. (NASDAQ: GILD), Abbott Laboratories (NYSE: ABT), Biogen Idec Inc. (NASDAQ: BIIB), and UnitedHealth Group Inc. (NYSE: UNH). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Amgen, Inc. Research Report

On September 11, 2013, Amgen, Inc. (Amgen) announced that a biomarker analysis of Vectibix (panitumumab) in combination with FOLFOX - an oxaliplatin-based chemotherapy, for the first time in patients with colorectal cancer (mCRC) - was published in the New England Journal of Medicine. Amgen stated that the analysis found that RAS mutations, beyond the known KRAS exon 2 mutations, predict lack of response to Vectibix in combination with FOLFOX. Amgen further informed that RAS mutations are ones found in exons 2, 3, and 4 of KRAS and NRAS. Jean-Yves Douillard, M.D., Ph.D., Professor of Medical Oncology Centre R. Gauducheau France and PRIME trial lead investigator and study author, said, "While the KRAS exon 2 biomarker is well-known and has facilitated selection of patients more likely to respond to anti-EGFR treatment. This analysis is important as it furthers our understanding of tumor genetics and allows physicians to more accurately match patients to effective treatments." The Full Research Report on Amgen, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []

Gilead Sciences, Inc. Research Report

On September 11, 2013, Gilead Sciences Inc. (Gilead) announced that the Company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for the approval of idelalisib, an investigational, targeted, oral inhibitor of PI3K delta for the treatment of indolent non-Hodgkin's lymphoma (iNHL). Gilead also informed that along with this NDA, the Company submitted data that supports the use of idelalisib for patients with iNHL that is refractory (non-responsive) to rituximab and to alkylating-agent-containing chemotherapy. The Company further added that it plans to file for regulatory approval of idelalisib in the European Union in Q4 2013. The Full Research Report on Gilead Sciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []

Abbott Laboratories Research Report

On September 4, 2013, Abbott Laboratories (Abbott) announced that preliminary results from a study evaluating Abbott's ARCHITECT STAT High Sensitive Troponin-I (hsTnI) test, which also received CE Mark in January 2013, were presented at the ESC Congress 2013. According to the Company, the study suggests that Abbott's high sensitive troponin test may help doctors improve the diagnosis and prognosis of patients presenting with symptoms of heart attack. The Company added that the test could be particularly beneficial for women, who may have different presenting symptoms, and are often under-diagnosed. Abbott's researchers shared data from the first 1,126 patients of the study presenting with symptoms of a heart attack. According to Abbott, early findings shows that women have lower peak levels of troponin than men, resulting to the under-diagnosis and therefore under-treatment of heart attacks for women. Abbott further informed that the ARCHITECT STAT hsTnI assay is commercially available in Europe, as well as Canada, Australia, New Zealand, and Brazil; however, the test is currently for research-use only in the US. The Full Research Report on Abbott Laboratories - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []

Biogen Idec Inc. Research Report

On September 9, 2013, Biogen Idec Inc. (Biogen Idec) announced that it has entered into a broad, multi-year collaboration with Isis Pharmaceuticals, Inc. (Isis) to leverage antisense technology to advance the treatment of neurological diseases. According to Biogen Idec, it will gain exclusive rights to the use of Isis' antisense technology to develop therapies for neurological diseases as part of the six-year research collaboration. According to the Company, the terms of the collaboration include: Biogen Idec will make an upfront payment of $100 million, which will be reflected as R&D expense in the Company's Q3 2013 financial results;  Isis is eligible to receive milestone payments, license fees, and royalty payments for all treatments developed through this collaboration, with the specific amount dependent upon the modality of the molecule advanced by Biogen Idec; and in the case of antisense molecules, the milestone payments could be as much as $220 million, plus additional amounts related to the cost of clinical trials conducted by Isis under the collaboration. The Full Research Report on Biogen Idec Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []

UnitedHealth Group Inc. Research Report

On September 11, 2013, UnitedHealth Group Inc. (UnitedHealth), Quality Health Solutions Inc. (QHS), and the Medical College of Wisconsin announced a new accountable care initiative that will provide coordinated care to over 100,000 Wisconsin residents enrolled in UnitedHealthcare's employer-sponsored health plans. According to the Company, the 3,000 physicians and 18 hospitals comprising five QHS members of the southeastern Wisconsin (Agnesian Healthcare, Columbia St. Mary's, Froedtert Health, Wheaton Franciscan Healthcare, and the Medical College of Wisconsin) will be rewarded for effectively managing all aspects of patients' care. In addition, QHS will offer primary care physicians ongoing status reports on their patients, allowing them to monitor each patient's care and maintain their clinical information in a secure patient registry. UnitedHealth further stated that the new initiative will go into effect on January 1, 2014. The Full Research Report on UnitedHealth Group Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []


  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by an analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
  5. For any urgent concerns or inquiries, please contact us at [email protected].
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.


Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Analysts' Corner